Log in

Evolus Stock Price, News & Analysis (NASDAQ:EOLS)

$14.01
-0.08 (-0.57 %)
(As of 10/13/2019 04:00 PM ET)
Today's Range
$13.95
Now: $14.01
$14.52
50-Day Range
$13.93
MA: $16.03
$18.72
52-Week Range
$10.22
Now: $14.01
$30.25
Volume169,925 shs
Average Volume345,136 shs
Market Capitalization$384.15 million
P/E RatioN/A
Dividend YieldN/A
Beta4.75
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EOLS
CUSIPN/A
Phone949-284-4555

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.09 per share

Profitability

Net Income$-46,870,000.00

Miscellaneous

Employees70
Market Cap$384.15 million
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable

Receive EOLS News and Ratings via Email

Sign-up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter.


Evolus (NASDAQ:EOLS) Frequently Asked Questions

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

How were Evolus' earnings last quarter?

Evolus Inc (NASDAQ:EOLS) announced its quarterly earnings data on Monday, August, 12th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($0.96) by $0.41. The company earned $2.30 million during the quarter, compared to analyst estimates of $0.29 million. View Evolus' Earnings History.

When is Evolus' next earnings date?

Evolus is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Evolus.

What price target have analysts set for EOLS?

8 analysts have issued 1 year target prices for Evolus' stock. Their predictions range from $13.00 to $37.00. On average, they anticipate Evolus' share price to reach $28.00 in the next twelve months. This suggests a possible upside of 99.9% from the stock's current price. View Analyst Price Targets for Evolus.

What is the consensus analysts' recommendation for Evolus?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evolus.

What are Wall Street analysts saying about Evolus stock?

Here are some recent quotes from research analysts about Evolus stock:
  • 1. According to Zacks Investment Research, "Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. " (8/15/2019)
  • 2. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution and ahead of what we expect to be a better-than-expected launch of Jeuveau, we are reiterating our OW rating and 12-month price target of $35. We think Jeuveau’s value proposition is underappreciated and that it will pick up more market share than anticipated. Therefore, the U.S. and other launches should drive EOLS’s stock higher, in our view." (4/30/2019)
  • 3. HC Wainwright analysts commented, "We think investors understand that Evolus will offer discounts and rebates off the list price, but we have sensed continued confusion over what Evolus is trying to accomplish by setting its list price where it did. While inconsequential for our financial model, Evolus’ move reinforces a couple important elements of the company’s commercial strategy. Signaling to consumers. The Evolus story has evolved since David Moatazedi became CEO last spring. Before Moatazedi took over, Evolus’ message primarily focused on the opportunity to compete on price. However, we think this message undersold the company’s product, since it implied Jeuveau, then known as DWP-450, was no different than other lower-cost BoNT-A products already on the market, Merz’s Xeomin." (4/4/2019)

Has Evolus been receiving favorable news coverage?

Media coverage about EOLS stock has been trending somewhat positive this week, InfoTrie reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Evolus earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Evolus.

Are investors shorting Evolus?

Evolus saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 4,847,000 shares, an increase of 11.0% from the July 31st total of 4,365,600 shares. Based on an average daily volume of 654,400 shares, the days-to-cover ratio is presently 7.4 days. Approximately 29.7% of the shares of the stock are sold short. View Evolus' Current Options Chain.

Who are some of Evolus' key competitors?

What other stocks do shareholders of Evolus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), Advanced Micro Devices (AMD), Revance Therapeutics (RVNC), Camtek (CAMT), Plug Power (PLUG), Micron Technology (MU), Tandem Diabetes Care (TNDM), JD.Com (JD), Canopy Growth (CGC) and Calithera Biosciences (CALA).

Who are Evolus' key executives?

Evolus' management team includes the folowing people:
  • Mr. David Moatazedi, Pres, CEO & Director (Age 41)
  • Ms. Lauren P. Silvernail, CFO & Exec. VP of Corp. Devel. (Age 60)
  • Mr. Michael Mazen Jafar, Chief Marketing Officer (Age 38)
  • Mr. Alejandro Sabad, VP of Operations
  • Mr. Ashwin K. Agarwal, VP of Fin., Investor Relations & Treasury

When did Evolus IPO?

(EOLS) raised $65 million in an IPO on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

How do I buy shares of Evolus?

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $14.01.

How big of a company is Evolus?

Evolus has a market capitalization of $384.15 million. The company earns $-46,870,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Evolus employs 70 workers across the globe.View Additional Information About Evolus.

What is Evolus' official website?

The official website for Evolus is http://www.evolus.com/.

How can I contact Evolus?

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected]


MarketBeat Community Rating for Evolus (NASDAQ EOLS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  233 (Vote Outperform)
Underperform Votes:  190 (Vote Underperform)
Total Votes:  423
MarketBeat's community ratings are surveys of what our community members think about Evolus and other stocks. Vote "Outperform" if you believe EOLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EOLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel